The current preferential boron compound used in glioblastoma patients is L-boronophenylalanine (L-BPA), so our group will consider further research on the effect of the combination use of PD-CD133/BSH and L-BPA for targeting glioma stem cells. This evidence concerns the gene PROM1 and glioblastoma.